| Dementia and Cognitive Impairment Research | Lifetime | 155 | SE 11 | 99.45 |
| Alzheimer's disease research and treatments | Lifetime | 189 | SE 9 | 99.48 |
| Retinal and Optic Conditions | Lifetime | 192 | SE 1 | 98.74 |
| Retinal Imaging and Analysis | Lifetime | 334 | SE 3 | 98.22 |
| Neuroprotection in Stroke and Neurodegeneration | Lifetime | 376 | SE 19 | 96.40 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 352 | SE 13 | 96.02 |
| Neurological Disease Mechanisms and Treatments | Lifetime | 735 | SE 28 | 94.58 |
| S100 Proteins and Annexins | Lifetime | 882 | SE 42 | 93.15 |
| Cancer-related cognitive impairment studies | Lifetime | 348 | SE 2 | 93.03 |
| Retinopathy of Prematurity Studies | Lifetime | 347 | SE 11 | 92.74 |
| Cerebral Venous Sinus Thrombosis | Lifetime | 900 | SE 10 | 92.10 |
| Alzheimer's disease research and treatments | 2021-2025 | 4 | SE 3 | 99.97 |
| Dementia and Cognitive Impairment Research | 2021-2025 | 4 | SE 3 | 99.98 |
| Cancer-related cognitive impairment studies | 2021-2025 | 3 | SE 1 | 98.12 |
| S100 Proteins and Annexins | 2021-2025 | 17 | SE 3 | 96.14 |
| Traumatic Brain Injury and Neurovascular Disturbances | 2021-2025 | 312 | SE 13 | 95.60 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 112 | SE 2 | 95.69 |
| Functional Brain Connectivity Studies | 2021-2025 | 534 | SE 10 | 95.55 |
| Intensive Care Unit Cognitive Disorders | 2021-2025 | 341 | SE 7 | 94.35 |
| Neuroinflammation and Neurodegeneration Mechanisms | 2021-2025 | 436 | SE 7 | 93.22 |
| Long-Term Effects of COVID-19 | 2021-2025 | 995 | SE 16 | 92.88 |
| Advanced Neuroimaging Techniques and Applications | 2021-2025 | 402 | SE 7 | 93.58 |
| Cardiac Arrest and Resuscitation | 2021-2025 | 775 | SE 25 | 93.27 |
| Neurological Disease Mechanisms and Treatments | 2021-2025 | 182 | SE 9 | 89.67 |
| Epilepsy research and treatment | 2021-2025 | 496 | SE 6 | 92.21 |
| Cerebrospinal fluid and hydrocephalus | 2021-2025 | 481 | SE 24 | 86.05 |
| Amyotrophic Lateral Sclerosis Research | 2021-2025 | 567 | SE 12 | 83.00 |
| Pharmacological Effects and Toxicity Studies | 2021-2025 | 757 | SE 10 | 80.45 |
| Neuroprotection in Stroke and Neurodegeneration | 2021-2025 | 740 | SE 11 | 69.33 |
| Down syndrome and intellectual disability research | 2021-2025 | 334 | SE 5 | 70.35 |
| Neurological diseases and metabolism | 2021-2025 | 643 | SE 8 | 65.55 |
| Neurological and metabolic disorders | 2021-2025 | 334 | SE 9 | 63.13 |
